Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase I, Randomized, Observer-blind, Active-controlled, Dose-escalation Trial Evaluating the Safety, Tolerability, and Immunogenicity of an Investigational RNA-based SARS-CoV-2 Vaccine in COVID-19 Vaccine Experienced Healthy Adults

NCT05541861 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT05541861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05541861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase I, Randomized, Observer-blind, Active-controlled, Dose-escalation Trial Evaluating the Safety, Tolerability, and Immunogenicity of an Investigational RNA-based SARS-CoV-2 Vaccine in COVID-19 Vaccine Experienced Healthy Adults
Lead sponsor
BioNTech SE
Phase
Phase 1
Overall status
Completed
Start date
November 8, 2022
Completion date
November 22, 2024
Enrollment
383 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection